Hemochromatosis, Type 4

1 clinical trials · Condition

Record	Firm	Date
Analysis of the Modulation of Serum Hepcidin Level in Response to Iron Oral Intake: Potential Interest for the Differential Diagnosis Between Ferroportin Disease and Dysmetabolic Hepatosiderosis. (NCT01949467)	Rennes University Hospital	2014-02-10

Every clearance here is in the API, with alerts when new ones post.